The continuing CRISPR patent battle: the Broad Institute loses a key European patent
In the ongoing CRISPR Cas9 gene-editing technology, the Broad Institute suffered a major blow in Europe with each side exploiting the idiosyncrasies of national patent laws in Europe and in the U.S.